Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has issued an announcement.
Imricor Medical Systems has announced that the University of Virginia Health Medical Center will become the second US site for its VISABL-AFL clinical trial, following IRB approval. This development marks a significant step in Imricor’s efforts to enhance MRI-guided electrophysiology ablations, with procedures expected to begin in February. The expansion to UVA Health is part of a broader strategy to ensure timely enrolment and FDA processes, positioning Imricor to strengthen its market presence and impact in the field of interventional cardiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a leader in developing MRI-compatible products for cardiac catheter ablation procedures. The company offers a range of products, including the NorthStar Mapping System and Advantage-MR EP Recorder/Stimulator, as well as various ablation and diagnostic catheters. Imricor’s products are approved in the EU, Saudi Arabia, and New Zealand, with ongoing efforts to secure US FDA approval and expand into other markets.
Average Trading Volume: 236,162
Technical Sentiment Signal: Buy
Current Market Cap: A$455M
Learn more about IMR stock on TipRanks’ Stock Analysis page.